Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

We evaluated the efficacy and safety of upadacitinib, an oral selective inhibitor of Janus kinase 1, as induction therapy for ulcerative colitis (UC).

Source link

Related posts

User-friendly tool helps identify colectomy risk in patients with UC


Study: Robotic Whipple Has Advantages Over Open Surgery


Complementary Medicine Use Ups Refusal of Usual Cancer Therapy


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy